Akums Drugs and Pharmaceuticals Gears Up for Q3 Reveal on 13th February. Check Key Expectations Here

Click and Sign Up to Get Live Updates on Q3 Results 

Akums Drugs and Pharmaceuticals’ Q3 results FY26 are scheduled to be announced on 13th February 2026. Financial analysts anticipate an increase in revenue due to higher sales and a significant rise in PAT.

Akums Drugs and Pharmaceuticals Q3 Results 2026 Preview

• Akums Drugs and Pharmaceuticals’ revenue is expected to be in the range of ₹75.04 crore, a 58.89% YoY increase. 
• Profit After Tax, or PAT, is projected to fall 2.19% YoY. 
• Net profit is ₹5.27 crore, a fall of 0.04% YoY 
• EBITDA to fall 9.32%

Akums Drugs and Pharmaceuticals Share Performance 

• Over the past six months, Akums Drugs and Pharmaceuticals’ share price has risen by 3.27% to ₹465.30.
• Moreover, over the past year, the stock has decreased by 15.39%.
• Despite this weak short-term performance, Akums Drugs and Pharmaceuticals’ stock has delivered a financially sound 42.07% return over the past 5 years.
• As of 12th February 2026, the stock traded at ₹465.30 per share.

About Akums Drugs and Pharmaceuticals

Akums Drugs and Pharmaceuticals was incorporated in 2004 and is an Indian pharmaceutical contract development and manufacturing organisation that operates with both domestic and multinational pharmaceutical companies. Its revenue was about ₹1,538.75 crore. The total assets at the end of FY2025 were about ₹2,095.43 crore.

Key Factors to Watch for Akums Drugs and Pharmaceuticals Q3 Results FY26

• Revenue Growth & Order Book

To check the company’s revenue growth, especially from contract manufacturing and export orders. A strong order book give positive signal for future growth.

• Operating Margins & Cost Control

To track the impact of raw materials, packaging, and logistics costs on margins, helping improve overall profitability through effective cost control.

• Client Addition & Retention

To effectively check whether the company has added new pharma clients and retained existing ones. Stable and increasing order reflects in business sustainability.

• Capacity Utilisation & Approvals

Monitor the capacity of manufacturing plants and the progress of capacity expansion projects to determine future revenue potential.

Final Thoughts

Akums Drugs and Pharmaceuticals will announce its Q3 FY26 results on 13th February 2026. Analysts expect 2.19% revenue growth, a 0.04% fall in PAT, and a 9.32% rise in EBITDA. Akums Drugs and Pharmaceuticals focuses on revenue growth from order execution, margin improvement, the strength of the order book, and management.

Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.

Download the Univest iOS App or Univest Android App to get daily stock recommendations and insightful research pieces!

Recent Articles

GOCL Corporation Q3 Results FY26 Preview

Godrej Industries Q3 Results FY26 Preview

Godawari Power and Ispat Q3 Results FY26 Preview

Hikal Q3 Results FY26 Preview

Himatsingka Seide Q3 Results FY26 Preview

Igarashi Motors India FY26 Preview

IG Petrochemicals Ltd Q3 Results FY26 Preview

IOL Chemicals & Pharmaceuticals Q3 Results FY26 Preview